Anti-FBXO32 Antibody

This polyclonal primary antibody targets FBXO32, also referred to as MAFbx or Atrogin-1, an F-box substrate-recognition component of the SCF E3 ubiquitin ligase complex that directs target proteins toward proteasomal degradation. Raised in rabbit and supplied as an unconjugated IgG at 100 µl per vial, it is validated for Western blot and immunohistochemistry on mouse and rat samples.

FBXO32 is most prominently studied in the context of skeletal muscle atrophy, where its transcript and protein levels rise rapidly under catabolic conditions including disuse, denervation, glucocorticoid exposure, fasting, and systemic illness such as cancer cachexia and sepsis. Researchers also deploy Anti-FBXO32 from Antibodies.com to probe cardiac stress responses, because the protein is induced in cardiomyocytes during hypertrophy and pressure-overload models. In metabolic disease research, FBXO32 has been linked to insulin-resistant and obese muscle phenotypes, and in aging studies it is a routine marker of sarcopenia progression.

The unconjugated format leaves secondary antibody choice and detection chemistry entirely in the user's hands, allowing HRP, alkaline phosphatase, or fluorescent readouts on demand. Working sample types include skeletal muscle lysates, heart tissue homogenates, and paraffin-embedded or snap-frozen tissue sections for IHC localization. For Western blot, lysates are commonly resolved under denaturing SDS-PAGE conditions, transferred to nitrocellulose or PVDF, and probed at empirically optimized dilutions.